Report
Christophe-Raphaël Ganet

Vetoquinol : Strong Q1 2020 sales (storage effect), cannot be extrapolated

>Q1 (+14%) above our expectations (precautionary purchases) - Vétoquinol published Q1 2020 sales of € 103.4m, (+13.7% and +13.4% at constant currency), including € 53.4m in essential products (+17.9% at constant currency / 51.6% of sales vs 48.4% for secondary products). Sales products intended for pets at € 60.1m represent 58.1% of the revenue (+15.1% at cc) compared to € 43.3m for production animals (41.9% of sales): +10.9% at cc.The group gave no guidance...
Underlying
Vetoquinol SA

V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Christophe-Raphaël Ganet

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch